Qatar

The primary regulatory authority for health products in Qatar is the Ministry of Public Health (MOPH), operating through its Pharmacy and Drug Control Department (PDCD) for pharmaceuticals and its Medical Devices Licensing and Registration Unit for medical devices, diagnostics, and related health technologies. The principal legislative framework is established under Law No. 8 of 1969 on the Practice of Pharmacy and its successive amendments, supplemented by Ministerial Decisions and circulars that govern product registration, importation, and post-market surveillance. All health products intended for the Qatari market must undergo a formal registration process prior to commercial distribution, with the MOPH maintaining a national registry of approved products. Digital health solutions and software as a medical device (SaMD) are subject to emerging guidance aligned with international frameworks, and applicants are advised to engage the MOPH early for classification determination.

Key submission requirements include the appointment of a locally registered pharmaceutical or medical device agent, who must hold a valid commercial registration in Qatar and acts as the legal representative for regulatory purposes. Dossiers are generally expected to conform to the Common Technical Document (CTD) format for pharmaceuticals, while medical device submissions align with internationally recognised standards such as those of the Gulf Cooperation Council (GCC) Standardization Organization (GSO) and the Medical Device Single Audit Program (MDSAP). Qatar participates in the GCC mutual recognition framework, meaning products registered in other GCC member states may benefit from an accelerated review pathway. Recent reforms include the digitisation of submission and tracking processes through the MOPH's eHealth portal, increased reliance on reference agency approvals from stringent regulatory authorities (such as the FDA, EMA, and Health Canada) as a basis for expedited registration, and the publication of updated guidance on post-market surveillance and pharmacovigilance obligations.

Public procurement of health products in Qatar is highly centralised, with Hamad Medical Corporation (HMC) serving as the dominant public healthcare provider and the principal institutional buyer for pharmaceuticals, medical devices, diagnostics, and digital health solutions. HMC operates its own procurement and supply chain division, which coordinates tender processes for hospital and clinical consumables across its network of facilities. The Primary Health Care Corporation (PHCC) manages procurement for community and primary care settings and issues separate tenders for its requirements. Both entities are subject to the national public procurement framework governed by Law No. 24 of 2015 on Regulation of Tenders and Auctions and supervised by the Ministry of Finance's Central Tenders Committee (CTC). Suppliers are generally required to be registered with the CTC and to operate through a locally registered agent or distributor. Formulary listing at HMC is a prerequisite for product uptake in the public sector and typically follows MOPH registration.

The private healthcare sector in Qatar is growing steadily, driven by investment from entities such as Sidra Medicine and a range of private hospital groups and polyclinics, which conduct their own procurement processes independently of the public tender framework. Qatar does not substantially rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, or Gavi, given its high-income country status and self-financing healthcare system. However, for specific public health initiatives or humanitarian programmes, international procurement mechanisms may occasionally be utilised in coordination with MOPH. Local manufacturing of health products remains limited, and Qatar does not currently impose formal local manufacturing preference policies; however, strategic national initiatives under Qatar National Vision 2030 encourage investment in domestic healthcare manufacturing capacity, and suppliers demonstrating local value contribution may benefit from favourable consideration in certain tender evaluations.